Breast cancer risk factors
Last month, we looked at two different types of genetic variants: BRCA variants and the KRAS-variant. Both BRCA and KRAS are pathogenic variants that are linked to an increased risk of breast…
Read More ➝
Cancer Treatment
Understanding different genetic causes of cancer: BRCA variants vs. the KRAS-variant
This post explores BRCA variants vs. the KRAS-variant and is part two in our series on understanding the different genetic causes of cancer. In part one of our series, we compared genetic…
Read More ➝
Understanding the different causes of cancer: genetic variants vs. genetic mutations
Learn more about how our genes play a role in cancer development in this two-part series comparing different genetic variants and genetic mutations. For Part 1, we’ll discuss the KRAS-variant and KRAS…
Read More ➝
Gennev Podcast Recap: HRT, Breast Cancer, Estrogen, and Menopause
Want to learn more about menopause, hormone replacement therapy (HRT), estrogen, and breast cancer risk? Why not sit down, pop in some headphones, and listen to this podcast from our partners at…
Read More ➝
New Clinical Trial for Treatment in Prostate Cancer Patients with Specific Genetic Biomarkers
Over the years, Mirakind has shared research and information about the KRAS-variant and how it can have many health implications – from cancer to autoimmunity to response to hormone replacement therapy. Now,…
Read More ➝
Clinical Trial for Patients with the KRAS-variant and HNSCC
Here on MiraKind.org, we’ve already discussed how the KRAS-variant plays a role in breast cancer risk, ovarian cancer risk, effects of HRT in the KRAS-variant patients, and even autoimmunity! Now, we want…
Read More ➝Doing Our Part to Support COVID 19 Testing and Our Path Forward
In May, Dr. Joanne Weidhaas did a webinar and Q&A session with members of our MiraKind community to share how MiraKind was using its available resources to help increase testing availability for…
Read More ➝MiraKind supports essential workforce organizations with free COVID-19 Testing
MiraKind is ready to distribute COVID-19 tests for free to essential workers, with funding from the generous philanthropic donations of our MiraKind community. We are currently prioritizing access to testing for facility…
Read More ➝
MiraKind Responds to the COVID-19 Pandemic
At MiraKind, we believe knowledge is power. That belief has never held truer than today, as we face a global pandemic that can only be stamped out with knowledge–knowledge of who is…
Read More ➝
Dr. Joanne Weidhaas to speak at TEDxCulverCity
Our founder, Dr. Joanne Weidhaas will be giving her first “TED talk” as an invited speaker at TEDxCulverCity on March 31, 2020! Joanne is a radiation oncologist and cancer researcher, and she…
Read More ➝
Let’s learn more about Hormone Replacement Therapy – together!
We want to start with the basics about Hormone Replacement Therapy, so you can get up to speed on the importance of MiraKind’s new study. In this article, we’ll cover what Hormone…
Read More ➝
New Partnership Alert: MiraKind & gennev
MiraKind is committed to providing our community with the best tools possible to tackle challenges in the arena of women’s health. This is why MiraKind is partnering with gennev, a first-of-its-kind telehealth…
Read More ➝
More proof Hormone Replacement Therapy (HRT) is safe, effective, and beneficial for most women
When our team came across a recent Los Angeles Times Article entitled, “Once and for all: Hormone replacement is good for women” we were very intrigued. What we learned from this game-changing…
Read More ➝
Important Findings From Our Recently Published KRAS-Variant Study
A new study by MiraKind’s Founder, Dr. Joanne Weidhaas, in collaboration with her team at the University of California, Los Angeles and City of Hope, has been published in the scientific journal…
Read More ➝
How Do I Get My DNA Test (KRAS-variant) Results?
Video 3 in our Ask Me Anything Series: Dr. Joanne Weidhaas answers your questions in our Ask Me Anything video series. Have a Question for Dr. Joanne? Submit your Q here
Read More ➝
